Bariatric Surgery and Pharmacokinetics of Gabapentin
ConditionObesity, Morbid
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorNorwegian University of Science and Technology
About this trial
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on gabapentin are investigated.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway
Being a Norwegian citizen
Disqualifiers
Having previously undergone resections in the GI-tract
Trial population
Patients referred for bariatric surgery (gastric bypass or sleeve gastrectomy)
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Gabapentin
DrugPatients are tested for their normal prescription gabapentin medication
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
gabapentin concentration in blood serum (area under curve (AUC))
Time frame
From baseline to 1 year postoperativelySponsors and contacts
Click on the lead sponsor to view all of their trials.
Norwegian University of Science and Technology
Lead sponsor
St. Olavs Hospital
Collaborator
Volvat Medisinsk Senter Stokkan
Collaborator
Namsos Hospital
Collaborator
Alesund Hospital
Collaborator
Source ClinicalTrials.gov